Harnessing producer cell lines and process intensification to address the AAV process productivity conundrum

Cell & Gene Therapy Insights 2024; 10(3), 299–307

DOI: 10.18609/cgti.2024.045

Published: 10 April
Ying Cai

In the battle to drive AAV process productivity to the levels required to ensure a successful commercial future, gene therapy developers are increasingly exploring non-traditional tools and methodologies. David McCall, Senior Editor, Cell & Gene Therapy Insights, talks to Ying Cai, Executive Director, Manufacturing Sciences and Technology, Ultragenyx, about the growing impact that producer cell lines and perfusion processes are having on manufacturing yields and consistency.